Patent Expiry
Patent/Exclusivity Expiry: EZALLOR SPRINKLE
Other upcoming events for NAMS
Phase 3 ReadoutPhase 3 Topline: A Placebo-controlled, Double-blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib/
Phase 3 ReadoutPhase 3 Topline: A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib
Patent ExpiryPatent/Exclusivity Expiry: ROSZET
Patent ExpiryPatent/Exclusivity Expiry: ATORVALIQ
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.